These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11899070)

  • 1. The molecular pathogenesis and experimental therapy of IgA nephropathy: recent advances and future directions.
    Hsu SI
    Curr Mol Med; 2001 May; 1(2):183-96. PubMed ID: 11899070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for genetic factors in the development and progression of IgA nephropathy.
    Hsu SI; Ramirez SB; Winn MP; Bonventre JV; Owen WF
    Kidney Int; 2000 May; 57(5):1818-35. PubMed ID: 10792601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of IgA nephropathy.
    Lai AS; Lai KN
    Curr Mol Med; 2005 Aug; 5(5):475-87. PubMed ID: 16101476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches?
    Floege J
    Am J Kidney Dis; 2011 Dec; 58(6):992-1004. PubMed ID: 21872377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of complement in IgA nephropathy.
    Tortajada A; Gutierrez E; Pickering MC; Praga Terente M; Medjeral-Thomas N
    Mol Immunol; 2019 Oct; 114():123-132. PubMed ID: 31351413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
    Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
    Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the pathogenesis of IgA nephropathy.
    Julian BA; Tomana M; Novak J; Mestecky J
    Adv Nephrol Necker Hosp; 1999; 29():53-72. PubMed ID: 10561737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Insights into the Pathogenesis of IgA Nephropathy.
    Robert T; Berthelot L; Cambier A; Rondeau E; Monteiro RC
    Trends Mol Med; 2015 Dec; 21(12):762-775. PubMed ID: 26614735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy.
    Medjeral-Thomas NR; O'Shaughnessy MM
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):111-119. PubMed ID: 32553243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease.
    Roos A; Rastaldi MP; Calvaresi N; Oortwijn BD; Schlagwein N; van Gijlswijk-Janssen DJ; Stahl GL; Matsushita M; Fujita T; van Kooten C; Daha MR
    J Am Soc Nephrol; 2006 Jun; 17(6):1724-34. PubMed ID: 16687629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
    Sawada A; Kawanishi K; Horita S; Koike J; Honda K; Ochi A; Komoda M; Tanaka Y; Unagami K; Okumi M; Shimizu T; Ishida H; Tanabe K; Nagashima Y; Nitta K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():48-52. PubMed ID: 26971743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glomerular diseases: emerging tests and therapies for IgA nephropathy.
    Canetta PA; Kiryluk K; Appel GB
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):617-25. PubMed ID: 24071652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA Nephropathy: Core Curriculum 2021.
    Pattrapornpisut P; Avila-Casado C; Reich HN
    Am J Kidney Dis; 2021 Sep; 78(3):429-441. PubMed ID: 34247883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin a nephropathy: Pathological markers of renal survival in paediatric patients.
    Fabiano RC; Pinheiro SV; de Almeida Araújo S; Simões E Silva AC
    Nephrology (Carlton); 2016 Dec; 21(12):995-1002. PubMed ID: 27414046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
    Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
    Front Immunol; 2019; 10():504. PubMed ID: 30941137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenetic and therapeutic approaches to IgA nephropathy using a spontaneous animal model, the ddY mouse.
    Tomino Y
    Clin Exp Nephrol; 2011 Feb; 15(1):1-7. PubMed ID: 21057848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future directions in the treatment of IgA nephropathy.
    Lai KN
    Nephron; 2002 Oct; 92(2):263-70. PubMed ID: 12218302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure.
    Chan LY; Leung JC; Lai KN
    Clin Exp Nephrol; 2004 Dec; 8(4):297-303. PubMed ID: 15619027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of podocyte injury in IgA nephropathy.
    Menon MC; Chuang PY; He JC
    Contrib Nephrol; 2013; 181():41-51. PubMed ID: 23689566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenetic aspects and gene polymorphisms of IgA nephropathy.
    Maixnerová D; Merta M; Reiterová J; Stekrová J; Rysavá R; Obeidová H; Tesar V
    Prague Med Rep; 2006; 107(2):171-88. PubMed ID: 17066738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.